Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
暂无分享,去创建一个
[1] J. Kuriyan,et al. Crenolanib is a selective type I pan-FLT3 inhibitor , 2014, Proceedings of the National Academy of Sciences.
[2] M. Mohty,et al. Allogeneic stem cell transplantation and targeted therapy for FLT3/ITD+ acute myeloid leukemia: an update , 2014, Expert review of hematology.
[3] M. Rudek,et al. TTT-3002 is a novel FLT3 tyrosine kinase inhibitor with activity against FLT3-associated leukemias in vitro and in vivo. , 2014, Blood.
[4] Alexander Kamb,et al. Preclinical Evaluation of AMG 925, a FLT3/CDK4 Dual Kinase Inhibitor for Treating Acute Myeloid Leukemia , 2014, Molecular Cancer Therapeutics.
[5] J. Aster,et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. , 2014, Cancer cell.
[6] M. Levis,et al. FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations , 2014, Leukemia & lymphoma.
[7] C. Chen,et al. Evaluation of the Antitumor Effects of BPR1J-340, a Potent and Selective FLT3 Inhibitor, Alone or in Combination with an HDAC Inhibitor, Vorinostat, in AML Cancer , 2014, PloS one.
[8] M. Levis,et al. Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants. , 2014, Blood.
[9] M. Shah,et al. An update on clinical trials of targeted therapies in thyroid cancer , 2014, Current opinion in oncology.
[10] Ø. Bruserud,et al. Antileukaemic effect of PI3K‐mTOR inhibitors in acute myeloid leukaemia‐gene expression profiles reveal CDC25B expression as determinate of pharmacological effect , 2014, British journal of haematology.
[11] M. Levis. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? , 2013, Hematology. American Society of Hematology. Education Program.
[12] K. Bhalla,et al. Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia , 2013, Pharmacotherapy.
[13] S. Baker,et al. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. , 2013, Blood.
[14] A. Fathi. Emergence of crenolanib for FLT3-mutant AML. , 2013, Blood.
[15] T. Kurosu,et al. Inhibition of the PI3K/Akt/GSK3 Pathway Downstream of BCR/ABL, Jak2-V617F, or FLT3-ITD Downregulates DNA Damage-Induced Chk1 Activation as Well as G2/M Arrest and Prominently Enhances Induction of Apoptosis , 2013, PloS one.
[16] J. Cortes,et al. Results Of a Phase 1 Study Of Quizartinib (AC220, ASP2689) In Combination With Induction and Consolidation Chemotherapy In Younger Patients With Newly Diagnosed Acute Myeloid Leukemia , 2013 .
[17] R. Hills,et al. AC220 (Quizartinib) Can Be Safely Combined With Conventional Chemotherapy In Older Patients With Newly Diagnosed Acute Myeloid Leukaemia: Experience From The AML18 Pilot Trial , 2013 .
[18] T. Clackson,et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. , 2013, The New England journal of medicine.
[19] J. Tamburini,et al. Predicting effects of kinase inhibitor in therapy for myeloid malignancies – the challenges in capturing disease heterogeneity , 2013, Expert opinion on investigational drugs.
[20] H. Kantarjian,et al. Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Lancet. New agents: great expectations not realized. , 2013, Best practice & research. Clinical haematology.
[22] S. Shurtleff,et al. Emergence of Polyclonal FLT3 Tyrosine Kinase Domain Mutations during Sequential Therapy with Sorafenib and Sunitinib in FLT3-ITD–Positive Acute Myeloid Leukemia , 2013, Clinical Cancer Research.
[23] I. Flinn,et al. Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study , 2013, British journal of haematology.
[24] H. Kantarjian,et al. Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy. , 2013, Clinical lymphoma, myeloma & leukemia.
[25] Jorge Cortes,et al. Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. , 2013, Blood.
[26] Z. Estrov,et al. Salvage therapy using FLT3 inhibitors may improve long‐term outcome of relapsed or refractory AML in patients with FLT3‐ITD , 2013, British journal of haematology.
[27] A. Younes,et al. Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib , 2013, Expert opinion on investigational drugs.
[28] Ø. Bruserud,et al. Pharmacologic targeting of the PI3K/mTOR pathway controls release of angioregulators from primary human acute myeloid leukemia cells and their neighboring stromal cells , 2013 .
[29] Ø. Bruserud,et al. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells , 2013, Oncotarget.
[30] Catherine C. Smith,et al. Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD. , 2013, Blood.
[31] Yoko Tabe,et al. Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. , 2013, Cancer letters.
[32] Z. Estrov,et al. A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) , 2012 .
[33] E. Estey,et al. Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation , 2012 .
[34] G. Nybakken,et al. Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML. , 2012, Blood.
[35] K. Götze,et al. High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses , 2012, Leukemia.
[36] N. Gray,et al. Using combination therapy to override stromal-mediated chemoresistance in mutant FLT3-positive AML: synergism between FLT3 inhibitors, dasatinib/multi-targeted inhibitors and JAK inhibitors , 2012, Leukemia.
[37] J. Griffin,et al. The STAT5 Inhibitor Pimozide Displays Efficacy in Models of Acute Myelogenous Leukemia Driven by FLT3 Mutations. , 2012, Genes & cancer.
[38] M. Heinrich,et al. Crenolanib Inhibits the Drug-Resistant PDGFRA D842V Mutation Associated with Imatinib-Resistant Gastrointestinal Stromal Tumors , 2012, Clinical Cancer Research.
[39] A. Krämer,et al. Survey and analysis of the efficacy and prescription pattern of sorafenib in patients with acute myeloid leukemia , 2012, Leukemia & lymphoma.
[40] S. Lok,et al. Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation. , 2012, Blood.
[41] M. Konopleva,et al. Targeting microenvironment-mediated resistance in leukemias: Phase I trial of mobilization and elimination of FLT3-ITD+ acute myelogenous leukemia (AML) stem/progenitor cells by plerixafor/g-CSF/sorafenib. , 2012 .
[42] S. Scholl,et al. Ponatinib may overcome resistance of FLT3‐ITD harbouring additional point mutations, notably the previously refractory F691I mutation , 2012, British journal of haematology.
[43] Andrew Kasarskis,et al. Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia , 2012, Nature.
[44] J. Esteve,et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] M. Mullane,et al. 5-flourouracil (5FU) shortage: Clinical implications and costs in a single month. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] C. Schiffer,et al. Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia , 2012, Leukemia.
[47] M. Konopleva,et al. Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.
[48] E. Estey,et al. A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results , 2011 .
[49] A. Kasarskis,et al. Validation of FLT3-ITD As a Therapeutic Target in Human Acute Myeloid Leukemia , 2011 .
[50] J. Wood,et al. Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia , 2011, Blood cancer journal.
[51] S. Shurtleff,et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] H. Kantarjian,et al. FLT3 inhibitors in the treatment of acute myeloid leukemia , 2011, Cancer.
[53] T. Clackson,et al. Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic Malignancies , 2011, Molecular Cancer Therapeutics.
[54] B. Smith,et al. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. , 2011, Blood.
[55] W. Wiktor-Jedrzejczak,et al. Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. , 2011, Blood.
[56] M. Konopleva,et al. Leukemia stem cells and microenvironment: biology and therapeutic targeting. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Torsten Haferlach,et al. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[58] M. Konopleva,et al. Phase I study of sorafenib in patients with refractory or relapsed acute leukemias , 2011, Haematologica.
[59] Lang Li,et al. Cyclic Administration of Combination of Sorafenib and Vorinostat In Poor-Risk AML: A Pharmacodynamically-Oriented Extended Phase I Trial , 2010 .
[60] N. Schmitz,et al. Sorafenib In Combination with Standard Induction and Consolidation Therapy In Elderly AML Patients: Results From a Randomized, Placebo-Controlled Phase II Trial , 2010 .
[61] Jiang Li,et al. mTOR signaling is activated by FLT3 kinase and promotes survival of FLT3-mutated acute myeloid leukemia cells , 2010, Molecular Cancer.
[62] E. Estey,et al. Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] M. Levis,et al. Bench to bedside targeting of FLT3 in acute leukemia. , 2010, Current drug targets.
[64] M. McDevitt,et al. A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias , 2010, Leukemia.
[65] Mark Brandt,et al. Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[66] B. Leber,et al. A randomized phase I clinical and biologic study of two schedules of sorafenib in patients with myelodysplastic syndrome or acute myeloid leukemia: a NCIC (National Cancer Institute of Canada) Clinical Trials Group Study , 2010, Leukemia & lymphoma.
[67] P. Zarrinkar,et al. AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML). , 2009, Blood.
[68] M. Konopleva,et al. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. , 2009, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[69] E. Estey,et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. , 2009, Blood.
[70] I. Bruns,et al. Sorafenib (Nexavar) induces molecular remission and regression of extramedullary disease in a patient with FLT3-ITD+ acute myeloid leukemia. , 2009, Leukemia research.
[71] S. Paggi,et al. Sorafenib in Advanced Hepatocellular Carcinoma , 2008 .
[72] M. Konopleva,et al. Mutant FLT3: a direct target of sorafenib in acute myelogenous leukemia. , 2008, Journal of the National Cancer Institute.
[73] M. Konopleva,et al. Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway , 2008, Leukemia.
[74] D. Gilliland,et al. Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin. , 2007, Blood.
[75] E. Estey,et al. Acute myeloid leukemia and myelodysplastic syndromes in older patients. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Apurva A Desai,et al. Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.
[77] E. Estey,et al. Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias , 2006, Molecular Cancer Therapeutics.
[78] E. Estey,et al. Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors. , 2006, Blood.
[79] S. Fröhling,et al. Cytogenetics and age are major determinants of outcome in intensively treated acute myeloid leukemia patients older than 60 years: results from AMLSG trial AML HD98-B. , 2006, Blood.
[80] D. Bowtell,et al. The multikinase inhibitor midostaurin (PKC412A) lacks activity in metastatic melanoma: a phase IIA clinical and biologic study , 2006, British Journal of Cancer.
[81] D. Small,et al. FLT3 mutations: biology and treatment. , 2006, Hematology. American Society of Hematology. Education Program.
[82] Dirk Strumberg,et al. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[83] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[84] D. Small,et al. FLT3 inhibitors: a paradigm for the development of targeted therapeutics for paediatric cancer. , 2004, European journal of cancer.
[85] C. Bloomfield,et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[86] G. Ehninger,et al. Analysis of Flt3-activating Mutations in 979 Patients with Acute Myelogenous Leukemia: Association with Fab Subtypes and Identification of Subgroups with Poor Prognosis , 2022 .
[87] C. Sawyers. Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia. , 2002, Cancer cell.
[88] Doriano Fabbro,et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. , 2002, Cancer cell.
[89] Donna Neuberg,et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). , 2002, Cancer cell.
[90] M. Baccarani,et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. , 2002, The New England journal of medicine.
[91] D. Grimwade,et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. , 2001, Blood.
[92] B. Smith,et al. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. , 2001, Blood.
[93] C. Sawyers,et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. , 2001, The New England journal of medicine.
[94] D. Small,et al. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation , 2000, Leukemia.
[95] T. Naoe,et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines , 2000, Oncogene.